...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses
【24h】

Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses

机译:需要高和低剂量华法林的意大利患者中VKORC1,CYP2C9和CYP4F2基因的重测序

获取原文
获取原文并翻译 | 示例

摘要

Purpose The aim of the present study was to investigate the genetic variability of VKORC1, CYP2C9 and CYP4F2 genes in patients who required a very low and high warfarin dose, in order to identify novel variants that could help to explain the particular extreme dose requirements. Methods Among patients followed and treated with warfarin at the Center of Haemostasis and Thrombosis of the PTV, we selected twelve patients showing a high divergence from warfarin standard doses required to achieve the therapeutic effect. All VKORC1, CYP2C9 and CYP4F2 coding regions, 3' and 5' UTR and exon/intron boundaries were analyzed by direct sequencing. Results The 1173T and -1639A allele variants in VKORC1 gene, associated with warfarin sensitivity, were present, as expected, mostly in low dose patients while 3730A allele, linked to warfarin resistance, has been found only in high dose patients. Interestingly, we found that three out of six low dose subjects presented CYP2C9*3/*3 homozygous genotype, very rare in Caucasians. Besides these common polymorphisms, we identified 5 SNPs in CYP2C9 gene and 19 SNPs in CYP4F2 gene. Among these, all polymorphisms identified in CYP2C9 gene were present only in low dose patients and three of them resulted in linkage with CYP2C9*2 and CYP2C9*3. Regarding CYP4F2 SNPs, we did not observe differences between the high and low dose patients. At the end, the whole sequencing did not reveal any novel polymorphism/mutation. Conclusion Further studies are required to identify other genetic factors contributing to extreme warfarin requirement.
机译:目的本研究的目的是调查需要高剂量和低剂量华法林的患者中VKORC1,CYP2C9和CYP4F2基因的遗传变异性,以鉴定有助于解释特定极端剂量需求的新型变异体。方法在PTV止血和血栓形成中心接受华法林治疗的患者中,我们选择了十二名与达到治疗效果所需的华法林标准剂量差异很大的患者。通过直接测序分析所有VKORC1,CYP2C9和CYP4F2编码区,3'和5'UTR以及外显子/内含子边界。结果正如预期的那样,在VKORC1基因中出现了1173T和-1639A等位基因变体,与华法林敏感性相关,主要在低剂量患者中出现,而与华法林抗性有关的3730A等位基因仅在高剂量患者中发现。有趣的是,我们发现六分之三的低剂量受试者呈现CYP2C9 * 3 / * 3纯合基因型,在高加索人中非常罕见。除了这些常见的多态性,我们在CYP2C9基因中鉴定出5个SNP,在CYP4F2基因中鉴定出19个SNP。其中,在CYP2C9基因中鉴定出的所有多态性仅在低剂量患者中存在,其中三个导致与CYP2C9 * 2和CYP2C9 * 3的连锁。关于CYP4F2 SNP,我们没有观察到高剂量和低剂量患者之间的差异。最后,整个测序未发现任何新颖的多态性/突变。结论需要进一步研究,以找出导致极端华法令需求的其他遗传因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号